Global Anticancer Biologics Market Strategic Research Report

Scope of the Report

The global Anticancer Biologics market size is predicted to grow from US$ 114,684 million in 2025 to US$ 217,860 million in 2032; it is expected to grow at a CAGR of 9.0% from 2026 to 2032.

Anticancer Biologics are a class of biologic medicines that use antibodies, proteins, cells, viruses, or other biologically derived substances as their primary active components to treat cancer through mechanisms such as specifically recognizing tumor-associated targets, modulating immune responses, directly eliminating tumor cells, blocking tumor growth signaling pathways, or altering the tumor microenvironment. Anticancer Biologics mainly include monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, cell therapies, cancer vaccines, and oncolytic virus therapies, and are widely used in the treatment of lung cancer, breast cancer, gastrointestinal cancers, hematologic cancers, and other malignant tumors.

Anticancer Biologics represent an important segment of modern cancer therapy and mainly include monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, cell therapies, cancer vaccines, and oncolytic virus therapies. Compared with conventional chemotherapy, Anticancer Biologics generally offer greater target specificity, more clearly defined mechanisms of action, and the ability to activate or modulate the immune system. They are widely used in the treatment of lung cancer, breast cancer, gastrointestinal cancers, hematologic cancers, and various other malignancies.

From an industry value-chain perspective, the upstream segment mainly includes cell lines, culture media, single-use bioreactors, chromatography media, filtration materials, pharmaceutical excipients, as well as key materials such as antibodies, payloads, and linkers. The midstream segment covers drug discovery, cell-line development, process development, drug-substance manufacturing, formulation, aseptic filling, quality control, and clinical development. Downstream demand mainly comes from general hospitals, oncology specialty hospitals, hematology treatment centers, and other specialized medical institutions. Antibody-based products are generally manufactured at scale through mammalian cell culture and bioreactor systems, with individual production lines ranging from several thousand liters to tens of thousands of liters in capacity, while cell therapies and cancer vaccines typically rely on smaller-batch, more flexible, and in some cases patient-specific manufacturing models.

The Anticancer Biologics industry is characterized by long development cycles, high technological barriers, stringent regulatory requirements, and substantial capital investment. Manufacturing costs are influenced by cell-culture productivity, protein expression levels, purification yields, raw material costs, production scale, and capacity utilization. Mature antibody products can generally achieve relatively attractive gross margins once large-scale production is established, while cell therapies, complex bispecific antibodies, and certain antibody-drug conjugates tend to carry higher manufacturing costs because of their more complicated production processes, smaller batch sizes, and stricter quality-control requirements. Advances in continuous manufacturing, single-use bioreactors, high-expression cell lines, and automated quality-control technologies are steadily improving manufacturing efficiency across the industry.

The competitive landscape is shaped by both large multinational pharmaceutical companies and biotechnology companies with differentiated technology platforms. Large pharmaceutical companies generally benefit from stronger capabilities in clinical development, global regulatory registration, commercialization, and large-scale manufacturing, while emerging biotechnology companies compete through innovative approaches such as bispecific antibodies, antibody-drug conjugates, cell therapies, and novel immuno-oncology targets. Chinese companies have developed rapidly in areas including PD-1/PD-L1 antibodies, bispecific antibodies, antibody-drug conjugates, and cell therapies, and are increasingly expanding into global markets through licensing agreements, co-development partnerships, and international clinical trials.

Looking forward, the Anticancer Biologics industry is expected to evolve from conventional single-target monoclonal antibodies toward bispecific and multispecific antibodies, next-generation antibody-drug conjugates, cell therapies, and combination treatments involving multiple mechanisms of action. Biomarker-based patient selection, precision treatment, subcutaneous formulations, long-acting formulations, and more efficient manufacturing processes are also expected to become increasingly important sources of clinical and commercial differentiation. As more biologic therapies move from later-line treatment into first-line, neoadjuvant, and adjuvant settings, Anticancer Biologics are expected to play an increasingly important role in the global cancer treatment landscape.

This report presents a comprehensive overview of the global Anticancer Biologics market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Antibody Therapies
• Antibody-Drug Conjugates (ADCs)
• Cell Therapies
• Cancer Vaccines and Oncolytic Viruses
• Others

Segment by Target

• Immune Checkpoint Targets
• Solid Tumor-Associated Targets
• Hematologic Tumor Targets
• Angiogenesis-Related Targets
• Others

Segment by Route of Administration

• Intravenous Administration
• Subcutaneous Administration
• Cell Infusion
• Intratumoral Administration
• Others

Segment by players, this report covers

• AbbVie Inc.
• Johnson & Johnson
• Novartis AG
• Gilead Sciences, Inc.
• Roche Holding AG
• Bristol-Myers Squibb Company
• Amgen Inc.
• AstraZeneca plc
• Merck & Co., Inc.
• Takeda Pharmaceutical Company Limited
• Merck KGaA
• Eli Lilly and Company
• Ono Pharmaceutical Co., Ltd.
• Pfizer Inc.
• GSK plc
• Regeneron Pharmaceuticals, Inc.
• Innovent Biologics, Inc.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• Shanghai Junshi Biosciences Co., Ltd.
• Akeso, Inc.
• Shanghai Henlius Biotech, Inc.
• RemeGen Co., Ltd.
• Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
• Sino Biopharmaceutical Limited
• Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
• Jiangsu Alphamab Biopharmaceuticals Co., Ltd.

Segment by Application

• Lung Cancer
• Breast Cancer
• Hematologic Cancers
• Gastrointestinal Cancers
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Anticancer Biologics market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Lung Cancer, Breast Cancer, Hematologic Cancers evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact